Assetmark Inc. Reduces Position in United Therapeutics Corporation $UTHR

Assetmark Inc. lowered its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 9.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 645,908 shares of the biotechnology company’s stock after selling 69,926 shares during the period. Assetmark Inc.’s holdings in United Therapeutics were worth $270,771,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Geneos Wealth Management Inc. raised its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. US Bancorp DE grew its position in shares of United Therapeutics by 16.6% during the second quarter. US Bancorp DE now owns 2,299 shares of the biotechnology company’s stock worth $661,000 after acquiring an additional 328 shares during the last quarter. Blair William & Co. IL grew its position in shares of United Therapeutics by 22.1% during the second quarter. Blair William & Co. IL now owns 1,343 shares of the biotechnology company’s stock worth $386,000 after acquiring an additional 243 shares during the last quarter. Concurrent Investment Advisors LLC boosted its position in United Therapeutics by 18.6% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 874 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 137 shares during the period. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in United Therapeutics by 16.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 8,184 shares of the biotechnology company’s stock worth $2,352,000 after purchasing an additional 1,170 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 0.1%

Shares of United Therapeutics stock opened at $476.13 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99. The company has a market cap of $20.50 billion, a P/E ratio of 18.04, a P/E/G ratio of 2.53 and a beta of 0.85. The stock has a 50-day moving average price of $486.33 and a 200 day moving average price of $431.32.

Analysts Set New Price Targets

Several brokerages recently commented on UTHR. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a report on Wednesday, October 29th. HC Wainwright lifted their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Finally, Royal Bank Of Canada raised their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

Insider Transactions at United Therapeutics

In other news, Director Christopher Causey sold 1,000 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $510.00, for a total value of $510,000.00. Following the completion of the sale, the director directly owned 4,190 shares in the company, valued at approximately $2,136,900. The trade was a 19.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $474.65, for a total transaction of $10,679,625.00. The SEC filing for this sale provides additional information. Insiders sold 502,214 shares of company stock valued at $242,241,993 in the last three months. Corporate insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.